NCT04508530

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Octapharma · Industry
• Sex: All
• Age: 6 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome

Conditions

• Pediatric Acute-Onset Neuropsychiatric Syndrome

Interventions

Type	Name	Description
BIOLOGICAL	Panzyga	Panzyga 10% IVIG
OTHER	Placebo	Placebo

Timeline

• Start date: 2021-06-30
• Primary completion: 2024-08-27
• Completion: 2024-10-30
• First posted: 2020-08-11
• Last updated: 2026-01-07
• Results posted: 2026-01-07

Locations

12 sites across 3 countries: United States, Italy, Sweden

Regulatory

• FDA-regulated drug study